Melanoma Clinical Trials

A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 261 clinical trials
Surgery of Melanoma Metastases After Systemic Therapy (SUMMIST)

To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma patients with partial response or stable disease after a minimum 9 months of first-line PD-1 inhibition

  • 0 views
  • 17 May, 2022
  • 1 location
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

This is an international multicenter, open-label, sequential phase study of intralesional (IL) PV-10 in combination with immune checkpoint inhibition. Metastatic melanoma patients (Stage IV or

neutrophil count
pembrolizumab
platelet count
metastatic melanoma
EGFR
  • 78 views
  • 13 Apr, 2022
  • 4 locations
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,

pembrolizumab
malignant melanoma of skin
metastatic melanoma
dabrafenib
serum pregnancy test
  • 0 views
  • 06 Apr, 2022
  • 7 locations
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

This is an open-labelled single arm trial of pembrolizumab and imatinib mesylate in subjects with unresectable or metastatic KIT-mutant melanoma that are refractory to standard therapy. The

immunologic adjuvant
pembrolizumab
metastatic melanoma
brain metastases
measurable disease
  • 0 views
  • 19 Apr, 2022
  • 1 location
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetinib 45 mg PO twice daily (BID) together with nivolumab

BRAF
cancer
braf inhibitor
ipilimumab
nivolumab
  • 5 views
  • 13 Apr, 2022
  • 1 location
A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation). It is also to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination …

BRAF
ipilimumab
pembrolizumab
nivolumab
advanced melanoma
  • 3 views
  • 23 Apr, 2022
  • 9 locations
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in

braf inhibitor
ipilimumab
malignant melanoma of skin
nivolumab
metastatic melanoma
  • 0 views
  • 23 Apr, 2022
  • 1 location
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.

immunologic adjuvant
BRAF
cancer
combinations
solid tumour
  • 0 views
  • 14 Apr, 2022
  • 6 locations
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

doses in combination with ipilimumab and nivolumab for four induction doses to week 12, then maintenance nivolumab alone up to one year to patients with advanced melanoma. Treatment will be divided into

immunologic adjuvant
cancer
ipilimumab
nivolumab
metastatic melanoma
  • 1 views
  • 26 Apr, 2022
  • 3 locations
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).

immunologic adjuvant
BRAF
measurable disease
vemurafenib
braf v600e mutation
  • 0 views
  • 04 May, 2022
  • 3 locations